ArticleJournal of neurology2014
Morphological features of MS lesions on FLAIR* at 7 T and their relation to patient characteristics.
Article in Journal of neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 58 citations in OpenAlex.
- Central Vein Sign Profile of Newly Developing Lesions in Multiple Sclerosis: A 3-Year Longitudinal Study.Neurology(R) neuroimmunology & neuroinflammation · 2022Trial
- Updates in Multiple Sclerosis Imaging.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025Review
- Inflammation-induced TRPV4 channels exacerbate blood-brain barrier dysfunction in multiple sclerosis.Journal of neuroinflammation · 2024Article
- The diagnostic value of the central vein sign in radiologically isolated syndrome.Annals of clinical and translational neurology · 2024Article
- The use of 7T MRI in multiple sclerosis: review and consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.Brain communications · 2024Review
- Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3-T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis.AJR. American journal of roentgenology · 2023Article
- Recent progress in epidemiology, clinical features, and therapy of multiple sclerosis in China.Therapeutic advances in neurological disorders · 2023Review
- Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- Stronger Microstructural Damage Revealed in Multiple Sclerosis Lesions With Central Vein Sign by Quantitative Gradient Echo MRI.Journal of central nervous system disease · 2022Article
- Iron Rims as an Imaging Biomarker in MS: A Systematic Mapping Review.Diagnostics (Basel, Switzerland) · 2020Review
- SWAN-Venule: An Optimized MRI Technique to Detect the Central Vein Sign in MS Plaques.AJNR. American journal of neuroradiology · 2020Article
- The Central Vein Sign in Radiologically Isolated Syndrome.AJNR. American journal of neuroradiology · 2019Article
- Interleaved susceptibility-weighted and FLAIR MRI for imaging lesion-penetrating veins in multiple sclerosis.Magnetic resonance in medicine · 2018Article
- Dark Rims: Novel Sequence Enhances Diagnostic Specificity in Multiple Sclerosis.AJNR. American journal of neuroradiology · 2018Observational
- Key clinical benefits of neuroimaging at 7T.NeuroImage · 2018Review
- MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.Therapeutic advances in neurological disorders · 2017Review
- The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.Nature reviews. Neurology · 2016Review
- MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.The Lancet. Neurology · 2016Review
- Relationship between iron accumulation and white matter injury in multiple sclerosis: a case-control study.Journal of neurology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, a new MRI technique was developed at 3 Tesla (T), called fluid attenuated inversion recovery* (FLAIR*). In this study, we implemented FLAIR* in an existing MS cohort at 7 T, to investigate whether we could corroborate results of previous 7 T studies that introduced specific MS lesion characteristics. Furthermore, we aimed to investigate the meaning of these lesion characteristics by relating them to clinical characteristics of the MS patient. Three-dimensional FLAIR and T2*-weighted images of 33 MS patients and 7 healthy controls were fused into FLAIR* images. Lesion type, signal intensity and morphology were analysed on FLAIR*, side-by-side with the original FLAIR and T2*, and correlated with clinical characteristics using Spearman's rho. Three morphological features of MS lesions were visualised: (1) central vessel (CV) within lesions, present in 78 % of total MS lesions; (2) hypointense rims around MS lesions, present in eight patients; (3) FLAIR* lesions that were hypointense at T2*, present in 13 patients. The presence of hypointense (rims around) lesions was not related to clinical characteristics. The simultaneous presence of rimlike lesions and hypointense lesions within MS patients was significantly correlated (ρ = 0.52, P < 0.01). We conclude that the implementation of the new MRI technique FLAIR* at ultra-high-field 7 T combines and corroborates the results of preceding 7 T research, by showing three morphological features of MS lesions. In addition, our study shows that these phenomena do not show a relation to patient's clinical characteristics and cannot be allocated to certain MS disease subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.